Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.
Last week, readers were most interested in a story about Tempus' offer to buy cancer diagnostic firm Personalis for $1.5 billion.
The second generation test can detect the Bundibugyo strain of the virus that currently poses a threat in the Democratic Republic of the Congo and nearby countries.
The lab firm said it now expects full-year net revenue in the range of $11.95 billion to $12.05 billion, up from its previous guidance of $11.78 billion to $11.90 billion.
NEW YORK – Based on data generated in the National Lung Screening Trial (NLST) cohort, cancer testing firm Mercy BioAnalytics believes its lung cancer early detection assay can identify cancers missed ...
The IVDR encompasses the firm's ER, PR, and Ki67 testing and completes certification of its overall digital pathology breast suite.
NEW YORK – Roche on Friday announced that its molecular test for vaginitis has received 510(k) clearance from the US Food and Drug Administration. The PCR-based Cobas BV/CV test uses ...
The approval allows the company to offer its PD-L1 IHC 22C3 pharmDx Code SK006 CDx for ovarian and other cancers.
The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.
NEW YORK – The Centers for Medicare & Medicaid Services issued a request for information Thursday seeking public input on potential updates to the Clinical Laboratory Improvement Amendments of 1988 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results